EVALUATION OF HETEROLOGOUS PRIME-BOOST IMMUNIZATION STRATEGY AGAINST BORDETELLA PERTUSSIS USING A NOVEL OUTER MEMBRANE VESICLE BASED VACCINE AND COMMERCIAL ACELLULAR VACCINE

MORENO GRISELDA; ZURITA MARÍA EUGENIA; GAILLARD M. EMILIA; DAVID SABATER MARTINEZ; RUMBO MARTÍN; DANIELA F. HOZBOR,

Congreso; LXIV Reunión Anual de la Sociedad Argentina de Inmunología (SAI); 2016

Sociedad Argentina de Inmunología (SAI)

Pertussis remains an important health problem in manycountries even in those with high vaccination coverage.From 1950s-1990s this disease was controlled by useof whole cell pertussis (wP) vaccines. Later in 2000sthese vaccines were replaced in developed countries byacellular pertussis a2 vaccines purified componentsof Bordetella pertussis (Bp) absorbed to alum). Thenew aP vaccines, although safer, are not as effectiveas the wP vaccine and this has been attributed to: 1)escape form protective immunity, 2) waning immunityor 3) a failure of the aP vaccine to induced protectivecellular immune responses. Under this context, wehave developed a new vaccine candidate based onouter membrane vesicles (OMVs) derived from Bpwhich is capable of inducing a more robust immuneresponse than commercial aP vaccines with a Th2/Th1/Th cellular profile. Here Ye evaluated the immunogenicityof a heterologous prime-boost regimen usingOMV-base and aP vaccines. For comparison purposeshomologous vaccination regimens with OMV basedvaccine and aP were also performed. For all cases, theinduced humoral and cell-mediated immune responseswere evaluated. A robust total IgG antibodies with ahigh IgG2a/IgG1 ratio were detected in sera of miceprimed with OMV based vaccine, suggesting that OMVssMeYed the immune response to a Th profile. Spleen cells from immunized mice were isolated and stimulatedin vitro with B. pertussis antigens. Interestinglythe obtained results showed that the priming with OMVvaccine induce a strong Th1/Th17 response with highvalues of INF-b (2100 ± 350 pg/ml p